vatalanib has been researched along with 2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide in 10 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide) | Trials (2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide) | Recent Studies (post-2010) (2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 17 | 0 | 3 |
| Protein | Taxonomy | vatalanib (IC50) | 2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 2.82 | |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | 0.38 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.64 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.236 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.1365 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.018 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0506 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (90.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bold, G; Brüggen, J; Furet, P; Haberey, M; Huth, A; Krüger, M; Manley, PW; Menrad, A; Mestan, J; Meyer, T; Ottow, E; Schnell, CR; Seidelmann, D; Siemeister, G; Thierauch, KH; Wood, J | 1 |
| Kiselyov, AS; Piatnitski, E; Semenov, VV; Semenova, M | 2 |
| Kiselyov, AS; Ouyang, S; Piatnitski, E; Semenov, VV; Semenova, M | 1 |
| Kiselyov, AS; Milligan, D; Semenov, VV; Semenova, M | 1 |
| Abrams, JM; Aegerter, S; Bayliss, PE; Bellavance, KL; Chan, J; Cowan, DB; Keating, MT; O'Reilly, T; Robbins, HS; Roberts, TM; Whitehead, GG; Wood, JM | 1 |
| Kiselyov, AS; Kisliy, VP; Piatnitski, EL; Samet, AV; Semenov, VV | 1 |
| Kiselyov, AS; Semenov, VV; Semenova, M | 2 |
| Jeong, KW; Kim, MS; Kim, Y; Lee, GS; Lee, K; Lee, Y; Song, JY | 1 |
10 other study(ies) available for vatalanib and 2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide
| Article | Year |
|---|---|
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.
Topics: Administration, Oral; Amides; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; CHO Cells; Cricetinae; Enzyme Inhibitors; Female; Humans; Isoquinolines; Lymphatic Metastasis; Melanoma; Mice; ortho-Aminobenzoates; Phosphorylation; Receptors, Vascular Endothelial Growth Factor | 2002 |
N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.
Topics: Amides; Animals; CHO Cells; Cricetinae; Enzyme Inhibitors; Inhibitory Concentration 50; Molecular Structure; Thiazoles; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.
Topics: Imidazoles; Inhibitory Concentration 50; Molecular Structure; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
Topics: Adenosine Triphosphate; Benzamides; Binding Sites; Fluorescence; Humans; Lipids; Models, Molecular; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template.
Topics: Caco-2 Cells; Enzyme Inhibitors; Humans; Models, Molecular; Pyridines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish.
Topics: Angiogenesis Inhibitors; Animals; Axons; Bone Regeneration; Endothelial Cells; Guided Tissue Regeneration; Heterozygote; Microscopy, Fluorescence; Mutation; Neurons; Phospholipase C gamma; Pigment Epithelium of Eye; Receptors, Vascular Endothelial Growth Factor; Regeneration; Skin Physiological Phenomena; Tissue Engineering; Zebrafish | 2006 |
ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2.
Topics: Adenosine Triphosphate; Azoles; Binding, Competitive; Caco-2 Cells; Cell Membrane Permeability; Humans; Inhibitory Concentration 50; Intestinal Absorption; Structure-Activity Relationship; Substrate Specificity; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2.
Topics: Adenosine Triphosphate; Caco-2 Cells; Combinatorial Chemistry Techniques; Drug Design; Humans; Indoles; Molecular Structure; Niacinamide; Oligonucleotides; Phthalazines; Pyridines; Structure-Activity Relationship; Thiazoles; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
(1,2,3-Triazol-4-yl)benzenamines: synthesis and activity against VEGF receptors 1 and 2.
Topics: Benzene Derivatives; Binding Sites; Humans; Triazoles; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
Topics: Drug Evaluation, Preclinical; Models, Molecular; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor Receptor-2 | 2010 |